This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Lymphomas Non-Hodgkin's B-Cell or Relapse
and you are
between 18 and 70
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

In this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10^6/kg-1×10^7/kg) will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with relapsed or refractory CD19 positive B-cell lymphoma.

Provided treatments

  • Biological: CD19 CAR T cells

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03029338. The sponsor of the trial is Institute of Hematology & Blood Diseases Hospital and it is looking for 20 volunteers for the current phase.
Official trial title:
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma